Physician profile
Maureen N Achuko
NPI 1245239136
$1,849.01
in general payments reported to CMS, 2019-2025
24 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $64.63 · 2022: $103 · 2023: $328 · 2024: $588 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $193.32 | 2023-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $170.43 | 2023-2025 | |
| Amgen INC. | $163.11 | 2020-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $145.62 | 2024 | Lupkynis |
| Ardelyx, INC. | $141.25 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Mallinckrodt Enterprises LLC | $137.35 | 2019 | |
| Horizon Therapeutics Plc | $136.68 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $131.13 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $115.63 | 2019-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $66.98 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $57.73 | 2022-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $55.05 | 2023 | Benlysta |
| Vifor Pharma, INC. | $54.97 | 2020-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $50.37 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $43.33 | 2024-2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $38.60 | 2022-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.61 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $20.23 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $19.70 | 2024 | Acthar |
| Lilly USA, LLC | $19.17 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $18.63 | 2025 | |
| Fresenius USA Marketing, INC. | $16.99 | 2023 | Velphoro |
| Shire North American Group INC | $15.65 | 2019 | |
| Boston Scientific Corporation | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Achuko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.